Cancer is a threat to human health. In addition to surgery, a variety of anticancer drugs are increasingly used in cancer therapy. However, despite the developments in multimodality treatment, the morbidity and mortality of patients with cancer patients are on the rise. During tumor progression, the tumor immunosuppressive microenvironment is considered to play a crucial role in immune escape and subsequent progression of tumors. The tumor-specific immunosuppressive microenvironment serves an important function in tumor tolerance and escape from immune surveillance. The tumor microenvironment (TME) has a decisive role in tumor differentiation, dissemination, and immune evasion. If the transformed cells evade immune control during the elimination phase, tumors are formed. As tumor cells and their stroma progress, the immunosuppressive mechanisms increase in magnitude.
The current trend in cancer therapy is based on chemotherapy and radiation therapy which not only kills cancer cells but also destroys immune cells. This causes complications. Therefore, a novel formulation comprising of new nutraceuticals that can enhance the tumor immune response is critical to develop improved cancer correction methods and chemotherapy and radiation treatment.
Increasing studies have shown that the interaction between the immune microenvironment and tumor cells is a process of dynamic equilibrium, which was called immunoediting. Immunoediting is the entire process of editing and shaping the immunosuppressive microenvironment.
The success of improved tumor microenvironment (TME) and cancer immunotherapy relies on the knowledge of the tumor microenvironment and the immune evasion mechanisms in which the tumor, stroma, and infiltrating immune cells function in a complex network. The potential barriers that profoundly challenge the overall clinical outcome of the promising therapies need to be fully identified and counteracted. Although cancer immunotherapy has increasingly been applied, we are far from understanding the method to utilize different strategies in the best way and combine therapeutic options to optimize clinical benefit.
SANJEEVANI is a unique nutraceutical which plays versatile roles in inhibiting a variety of biological functions of tumors, including growth, proliferation, invasion, metastasis, apoptosis, angiogenesis and drug resistance of tumor cells.
SANJEEVANI inhibits tumors through enhancement of the anticancer immune response, remodels the tumor immunosuppressive microenvironment and exerts influence on lymphocyte infiltration, such as cytotoxic T cells (CTL), Foxhead p3(FOXP3)+ regulatory T cells (FOXP3+Tregs) and natural killer (NK) cells and the M1 to M2 macrophage transformation in the process of innate immunity.
The invasion and metastasis ability of tumor cells is a common cause of tumor treatment failure and SANJEEVANI can significantly inhibit these activities in tumor cells.
The growth of a solid tumor depends on tumor neovascularization. Angiogenic factors such as VEGF, hypoxia‑inducible factor‑1α, angiopoietin‑1 and ‑2 and interleukin‑2, ‑8 and ‑17 are closely associated with tumor neovascularization. These factors can be modulated by SANJEEVANI to remodel tumor neovascularization.
The intrinsic resistance and adaptive resistance of tumors to chemotherapeutics are important reasons for chemotherapy failure. Therefore, identifying efficient chemotherapy sensitizers is important to address this problem. SANJEEVANI has been found to play specific roles in resensitizing certain types of cancers to chemotherapy.
SANJEEVANI not only inhibits tumors by affecting the biological behaviors of tumor cells, but it also regulates the composition of different components in the tumor immune microenvironment, so that the immune microenvironment is conducive to tumor killing.
Innate immune cells, such as Dendritic cells (DCs), macrophages and NK cells, recognize tumor‑associated antigens and stimulate cytotoxic effects thereby killing the tumor cells. NK cell activity is particularly essential and is compromised of conventional treatments such as chemotherapy and radiotherapy that have weakened the immune system. NK cell activity is particularly essential because NK cells specifically target many types of cancer and the blood of cancer patients typically has less than half the NK cell activity of a healthy individual and often even less if conventional treatments such as chemotherapy and radiotherapy have weakened the immune system.
Macrophages represent up to 50% of the cells infiltrating into the tumor microenvironment (TME) and modulation of macrophage polarization is an interesting and novel therapeutic approach in preclinical or clinical cancer research. An increasing number of studies have also shown that tumor-associated macrophages (TAMs) can antagonize, augment or mediate the antitumor effects of cytotoxic agents, tumor irradiation, anti-angiogenic/vascular damaging agents and checkpoint inhibitors.